DexCom, Inc. (DXCM)

DexCom Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	639.3	541.5	341.2	216.9	549.7	101.1
Depreciation & Amortization	196.9	186	155.9	102	67.1	48.7
Share-Based Compensation	154.6	150.8	126.5	113.4	119.4	102.7
Other Operating Activities	-188.5	-129.8	45.9	10.2	-260.6	62
Operating Cash Flow	802.3	748.5	669.5	442.5	475.6	314.5
Operating Cash Flow Growth	6.42%	11.80%	51.30%	-6.96%	51.22%	155.28%
Capital Expenditures	-218.8	-236.6	-364.8	-389.2	-199	-180
Acquisitions	0	0	-3.9	-30.2	0	0
Change in Investments	-11.6	-253	-138.5	193.2	-807.7	-834
Other Investing Activities	-15.3	-17.6	-14.3	10.1	-11.3	-1.2
Investing Cash Flow	-245.7	-507.2	-521.5	-216.1	-1,018	-1,015.2
Share Issuance / Repurchase	-661	-662.1	-535.2	20.3	15.3	11.9
Debt Issued / Paid	443.3	443.3	0	0	906.2	0
Other Financing Activities	-107.4	-99.8	-17.3	-9.9	-9.4	-1.2
Financing Cash Flow	-325.1	-318.6	-552.5	10.4	912.1	10.7
Exchange Rate Effect	-3.4	1.5	-5.8	-1.4	2.1	-0.7
Net Cash Flow	228.1	-75.8	-410.3	235.4	371.8	-690.7
Free Cash Flow	583.5	511.9	304.7	53.3	276.6	134.5
Free Cash Flow Growth	40.26%	68.00%	471.67%	-80.73%	105.65%	139.75%
Free Cash Flow Margin	15.35%	14.13%	10.47%	2.18%	14.36%	9.11%
Free Cash Flow Per Share	1.50	1.33	0.78	0.14	0.73	0.37

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).